📰Out NOW in @CancerCell ‼️👉cell.com/cancer-cell/fu… 🎉What underpins anti-PD-1 response in ccRCC?

Results from ADAPTeR Phase II clinical trial, bulk/single-cell analysis of longitudinal tumour samples ⤵️(1/15) @royalmarsdenNHS @TheCrick @uclcancer
Intratumour heterogeneity (ITH) is pervasive in ccRCC & longitudinal data on anti-PD1 response is scarce 🚨 Thus we performed multi-omics analysis on 115 multiregion tumour samples, taken at baseline, week-9, & PD, from 15 treatment-naïve patients treated with nivo 🔬 (2/15)
What are the determinants of anti-PD1 response? 🤔 In keeping with other studies, no nsSNV/fsINDEL/copy number event, nor TMB/wGII (measure of chromosomal complexity) correlated with response, pre or post-nivo, even accounting for ITH (3/15)
BONUS👀One case - enabled by post-mortem sampling - we saw uncharacteristic high TMB underpinned by MLH1 mutation with loss of antigen presentation (B2M) was driving differential response. Nivo-resistant metastases had these features, responsive sites did not. Interesting! (4/15)
On RNAseq, we found 1) HERVs expression signatures previously associated with IO benefit, mostly come from immune cells. Therefore, prior associations were likely indirect; 2) ccRCC-specific HERVs reflect tumour purity (5/14)
Next, pre/post-nivo RNAseq show T cell activation and upregulation of TCR signalling in responders. IHC/mIHC show responders upregulate GZMB post-nivo 🚨 These dynamic changes warranted dedicated investigation ➡️ we then performed TCRseq & single-cell sequencing, (6/15)
At baseline, high TCR clonality correlated with response. Tracking total TCR repertoires post-treatment...✔️ In responders, expanded TCRs that were maintained on nivo ❌ In non-responders, expanded TCRs were replaced. This was observable in tumours, not in PBMC (7/15)
In responders, TCR clustering analysis (of similar CDR3 sequences) show expanded TCR clones had more cluster structure than non-responders – pre & post-nivo. This supports existence of T cells likely recognising tumour antigen(s) & are maintained with nivo in responders (8/15)
BONUS 👀 2nd patient with differential response. TCRseq of nivo-responsive metastases show maintained expanded TCRs present during life & response. Resistant sites had only novel TCR clones #PEACEstudy (9/15)
Next, we isolated TILs from a responder & a non-responder who underwent nephrectomy at week 9 of nivo. This provided adequate material for flow cytometry & single-cell analysis of the exact CD8 T cells nivolumab were bound to. 🤿 A deep-dive! (10/15)
Paired scRNA/TCRseq show a ‘hyperexpanded’ population of nivolumab-bound CD8 T cells in the responder. 🔵🔵🔵These T cells had a cytotoxic phenotype and had more cluster structure. These features were not found in the nivo-bound T cells from the non-responder (11/15)
To confirm these findings, we performed a meta-analysis using external scRNA/TCRseq datasets. In >100,000 CD8 T cells, despite inherent differences in treatment regimens and sampling timepoints, we found CD8 T cells from IO responders were expanded and upregulated GZMK (12/15)
Summary - Longitudinal tumour profiling during anti-PD-1 showed ✅ Expanded TCRs pre-treatment ✅Maintenance of expanded TCRs in responders ✅ Nivo binds pre-existing expanded CD8 T cells to enhance cytotoxicity (13/15)
A big THANK YOU to @royalmarsdenNHS as study sponsor & the incredible research team. 🎉Our wonderful collaborators @uclcancer @squezadd @BennyChain and @CharlesSwanton @MariamJHanjani @kevlitchfield & George Kassiotis @TheCrick and many more 🎉(14/15)
Finally, to @lewisjwau @emine_h @MarcRdM who led on the work. Funders @royalmarsden @CR_UK @cancerBRC @UCLHresearch. But most importantly, to the patients and their families, for their generosity, and putting their trust in us in this study 🙏 Thank you (15/15)

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Turajlic Lab @ The Crick

Turajlic Lab @ The Crick Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @TurajlicLab

27 Oct
2nd paper 📰📰 Vaccine Cohort 💉 We analysed vaccine responses in 585 patients with cancer after COVID-19 vaccination, measuring neutralising responses against the original SARS-CoV-2 and variants of concern (incl. Delta) and T cell responses (1/11)
After two doses of either Pfizer-BionTech or Oxford-AstraZeneca, 83% of infection-naïve patients with cancer developed antibodies against the original strain, but only 54% of those had neutralising antibodies against Delta (2/11)
Importantly, we show that while the proportion of patients with S1-reactive antibodies is concordant to patients with NAb against WT SARS-CoV-2 it can overestimate neutralising responses against variants of concern (3/11)
Read 11 tweets
27 Oct
1st paper📰 Infection Cohort 👉We analysed neutralising and T cell responses in 118 patients with cancer, where SARS-CoV-2 infection was defined by positive PCR or antibody test. COVID-19 severity ranged from asymptomatic to severe (1/6) nature.com/articles/s4301…
Most patient with solid cancer had neutralising antibodies while blood cancer patients had reduced or absent neutralising responses (2/6)
Patients who were infected with either the original strain or the Alpha variant had neutralising responses that were reduced against the Beta and Delta variants (3/6)
Read 6 tweets
27 Oct
Two papers OUT NOW in @NatureCancer ‼️ What does the immune response in cancer patients look like after COVID-19 vaccination or SARS-CoV-2 infection? We present results from the #CAPTURE study. Two-part thread (vaccine & infection cohort findings) to follow... 🧵🧵 (1/4) https://www.nature.com/articles/s43018-021-00274-whttps://www.nature.com/articles/s43018-021-00275-9
About the study: #CAPTURE a prospective, longitudinal cohort study established in April 2020 and conducted at @royalmarsdenNHS and @TheCrick. #CAPTUREstudy recruitment and analyses are ongoing (2/4) cell.com/cell/fulltext/…
CAPTURE assessed functional immunity in cancer patients – given registry studies @COVID19nCCC @UKCORONACANCER show cancer patients are vulnerable to COVID19 & vaccines induce robust adaptive immunity but may be lower in blood cancer patients @EJohnWherry @florian_krammer (3/4)
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(